Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
ORGO Stock | USD 2.75 0.07 2.61% |
About 54% of Organogenesis Holdings' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Organogenesis Holdings suggests that some traders are interested. Organogenesis Holdings' investor sentiment overview provides quick insight into current market opportunities from investing in Organogenesis Holdings. The current market sentiment, together with Organogenesis Holdings' historical and current headlines, can help investors time the market. In addition, many technical investors use Organogenesis Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Organogenesis |
Statistically significant reduction in knee pain at six monthsStatistically significant maintenance of function at six monthsTransformational opportunity for Organogenesis to enter large and growing pain management market with innovative therapyWill address critical unmet medical need for all knee OA patients, including the most severe, if approved CANTON, Mass., May 02, 2024 -- Organogenesis Holdings Inc. , a leading regenerative medicine com
Read at finance.yahoo.com
Organogenesis Holdings Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Organogenesis Holdings can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Organogenesis Holdings Fundamental Analysis
We analyze Organogenesis Holdings' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Organogenesis Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Organogenesis Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Organogenesis Holdings is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Organogenesis Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Organogenesis Holdings stock to make a market-neutral strategy. Peer analysis of Organogenesis Holdings could also be used in its relative valuation, which is a method of valuing Organogenesis Holdings by comparing valuation metrics with similar companies.
Peers
Organogenesis Holdings Related Equities
COLL | Collegium Pharmaceutical | 5.84 | ||||
ALIM | Alimera Sciences | 3.08 | ||||
NBIX | Neurocrine Biosciences | 1.43 | ||||
TKNO | Alpha Teknova | 1.16 | ||||
ITCI | Intracellular | 0.88 | ||||
GHSI | Guardion Health | 0.30 | ||||
DCPH | Deciphera Pharmaceuticals | 0.08 | ||||
TARO | Taro Pharmaceutical | 0.21 | ||||
ALKS | Alkermes Plc | 1.03 | ||||
DVAX | Dynavax Technologies | 1.71 | ||||
LFCR | Lifecore Biomedical | 2.48 | ||||
PTPI | Petros Pharmaceuticals | 4.00 | ||||
LSDI | Lucy Scientific | 4.76 | ||||
SHPH | Shuttle Pharmaceuticals | 7.84 | ||||
RDHL | Redhill Biopharma | 10.42 |
Additional Information and Resources on Investing in Organogenesis Stock
When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock:Check out Organogenesis Holdings Hype Analysis, Organogenesis Holdings Correlation and Organogenesis Holdings Performance. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 11.307 | Earnings Share 0.04 | Revenue Per Share 3.313 | Quarterly Revenue Growth 0.022 | Return On Assets 0.0201 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.